Claim Missing Document
Check
Articles

Found 4 Documents
Search

ATROPINE 0.01% AS A POTENTIAL MYOPIA PREVENTION IN CHILDREN WITH DOSAGE EFFECTIVITY COMPARISON: A LITERATURE REVIEW Ivan, Ignatius; Stella, Maureen Miracle; Santosa, Mariani
Jurnal Kedokteran YARSI Vol 27, No 3 (2019): SEPTEMBER - DESEMBER 2019
Publisher : Lembaga Penelitian Universitas YARSI

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (187.31 KB) | DOI: 10.33476/jky.v27i3.1114

Abstract

Myopia (long-sightedness) is one of the many problems of vision disorder occurring around the world and being 1 in 5 eye conditions that becoming a priority at the World Health Organization's Global Intitiative for the Elimination of Avoidable Blindness. Many methods of preventing myopia development have been sought. Atropine is an alkaloid derived herbal plant Atropa belladonna which acts as a muscarinic acetylcholine receptor antagonist that has a strong nonselective competitive affinity on the five types of muskarinic acetylcholine receptors (M1-M5) that weaken the muscles of the ciliary and iris and causes the reduction of accommodation and the occurrence of pupil dilation. Recent research found that with the use of low dose atropine (0.01%), in addition to the side effects inflicted more minimal, effectiveness in the long time period shows better results. Until now, the  mechanism of atropine is still experiencing debate whether working on an accommodating or non-accommodating pathway. But recent research suggests the possibility of working mechanism of this drug is through a non-accommodating pathway i.e. on GABAergic, dopaminergic as well as involving nitric oxide (NO) role to help inhibit the progression of myopia. In research and advanced scientific studies, it can be researched regarding the pathways of atropine mechanism and its advantages and disadvantages at any dose of atropine given to myopia sufferers using the latest literature sources.
Skin manifestations in patients with covid-19: A literature review Gunawan, Danny; Stella, Maureen Miracle; Sidharta, Veronika Maria
Sains Medika: Jurnal Kedokteran dan Kesehatan Vol 13, No 1 (2022): June 2022
Publisher : Faculty of Medicine, Universitas Islam Sultan Agung (UNISSULA), Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1237.235 KB) | DOI: 10.30659/sainsmed.v13i1.15563

Abstract

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. In December 2019, cases of pneumonia with unknown cause were first reported in Wuhan, Hubei Province, China. Confirmed cases and death rates due to COVID-19 in the world are still increasing. One part of the body that is affected and causes clinical symptoms in COVID-19 is the skin. This review aims to describe and analyze cutaneous manifestation in COVID-19. This study method is a review of the literature sourced from Google Scholar and PubMed. The literature was selected using English language criteria, using the clinical study method in the form of case reports. Meanwhile, literature review, systematic literature, and meta-analysis were excluded. Journal searches were carried out using the keywords "skin" OR "cutaneous" AND "manifestation" AND "COVID-19" OR "coronavirus". The skin manifestations of COVID-19 have been observed. The most common clinical symptoms of COVID-19 were fever (47%), dry or productive cough (25%), sore throat (16%), generalized sore throat (6%), and pain (5%). However, currently there has been a shift in the approach to diagnosing COVID-19 because it can cause symptoms in other organ systems, one of which is skin manifestations. There are early reports of skin involvement (erythematous rash, extensive urticaria, and chickenpox-like vesicles) occurring in 20% of patients in the course of the COVID-19 disease. In addition, several case reports provide descriptions of petechiae and chilblains. Based on the cases that have been reported, patients with COVID-19 who have manifestations on the skin can give a picture of maculopapular eruptions, vesicular eruptions, petechiae, and also childblains.
Plasmodium falciparum Breath Metabolomics (Breathomics) Analysis as a Non-Invasive Practical Method to Diagnose Malaria in Pediatric Ivan, Ignatius; Stella, Maureen Miracle; Tandarto, Kevin; Budiman, Fanny; Joprang, Freggy Spicano
Indonesian Journal of Tropical and Infectious Disease Vol. 9 No. 1 (2021)
Publisher : Institute of Topical Disease Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/ijtid.v9i1.24069

Abstract

Children under 5 years of age are particularly vulnerable to malaria. Malaria has caused 445,000 deaths worldwide. Currently, rapid diagnostic tests (RDTs) are the fastest method to diagnose malaria. However, there are limitations that exist such as low sensitivity in detecting infections with low parasitemia. Practical, non-invasive and high ability tests to detect parasite are needed to find specific biomarkers for P. falciparum infection to determine the potential of P. falciparum 4 thioether in breathomics analysis by GC-MS as a practical non-invasive method in diagnosing malaria in pediatrics. Literature reviews from Google Scholar and ProQuest were published no later than the last 5 years. The concept of breathomics is that the breath's volatile organic compounds (VOCs) profile is altered when the health condition changes. Breath samples from individuals infected with P. falciparum malaria were taken by exhalation. Through GC-MS analysis, it was found that 4 thioether compounds (allyl methyl sulfide (AMS), 1-methylthio-propane, (Z) -1-methylthio-1-propene and (E) -1-methylthio-1-propene) underwent a significant change in concentration during the infection. Based on experiments conducted on mice and humans, the breathomics method is known to be able to detect parasitemia levels up to <100 parasites/µL, has a sensitivity level of about 71% to 91% and a specificity of about 75% to 94%. The discovery of 4 thioether compounds by GC-MS is a strong indication of malaria, because it has the potential for high sensitivity and specificity, and the detection power exceeds the ability of RDTs.
Zoliflodacin, A Novel Antimirobial Agent Against neisseria Gonorhoeae: A Systematic Rreview of Quasi-Experimental Studies Matthew, Franklind; Stella, Maureen Miracle; Tandarto, Kevin; Regina, Regina
Berkala Ilmu Kesehatan Kulit dan Kelamin Vol. 36 No. 1 (2024): APRIL
Publisher : Faculty of Medicine, Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/bikk.V36.1.2024.68-74

Abstract

Background: The gram-negative bacteria Neisseria gonorrhoeae is the source of the STI known as gonorrhea. N. gonorrhoeae can adapt well to humans as a host and become a pathogen with sophisticated mechanisms to avoid the innate immune response as well as suppress the adaptive immune response. Lately, zoliflodacin was shown to have antibacterial activity against N. gonorrhoeae. Purpose: The aim of this study is to evaluate the antibacterial activity of zoliflodacin against N. gonorrhoeae. Methods: We followed the PRISMA 2020 guidelines to systematically search and collect literature in the following databases: ProQuest, EBSCOhost, PubMed, ScienceDirect, Taylor&Francis, SAGE, JSTOR, and Wiley, without time limitation (until October 9th,  2022). Titles and abstracts were reviewed for relevance. The inclusion criteria were original article written in English that investigated the effects of zoliflodacin in patients with gonorrhea. From 177 studies, we retrieved five studies for this study, published between 2015 and 2021. Results: Zoliflodacin was highly active in vitro against N. gonorrhoeae isolates from European countries, China, Thailand, and South Africa, and also showed potent antimicrobial activity against multi-resistant N. gonorrhoeae isolates in South Korea. There were three different kinds of minimum inhibitory concentration (MIC) evaluated, with the following results: modal MIC (0.064-0.25 μg/mL), MIC50 (0.03-0.125 μg/mL), and MIC90 (0.06-0.25 μg/mL). There was no cross-resistance to antimicrobials currently or previously used for gonorrhea treatment. This MIC range could be used for further studies.